Huang Yijie, Chen Yexi, Lin Xiaoqi, Lin Qingjun, Han Ming, Guo Guohu
Department of General Surgery, Guangdong General Hospital, Guangzhou.
Department of General Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, People's Republic of China.
Onco Targets Ther. 2017 Sep 20;10:4665-4673. doi: 10.2147/OTT.S144638. eCollection 2017.
Stomatin-like protein 2 () gene was significantly upregulated in a variety of tumor tissues and found to be involved in proliferation and metastasis. However, its functional role in hepatocellular carcinoma (HCC) remains unknown. Our study was to investigate the function of SLP-2 in cell proliferation, migration, invasion, cell apoptosis, and the process of epithelial-mesenchymal transition (EMT) in HCC. SLP-2 mRNA and protein expression in HCC were assessed by qRT-PCR and immunohistochemical staining. In vitro, we determined cell proliferation, migration, invasion, and cell apoptosis by CCK-8, transwell, and flow cytometry assays, respectively. SLP-2 was found to be upregulated at both mRNA and protein levels in HCC tissues, and its aberrant overexpression was linked with poor prognosis in patients with HCC. SLP-2 downregulation by siRNAs significantly suppressed cell proliferation, migration, invasion, anti-apoptosis abilities, and inhibited EMT process in vitro. In conclusion, the present study demonstrated the overexpression of SLP-2 in HCC tissues for the first time. As an effective regulator involved in cell proliferation, migration, invasion, cell apoptosis, and EMT, SLP-2 could be a novel therapeutic target for patients with HCC who express high levels of SLP-2.
类stomatin蛋白2()基因在多种肿瘤组织中显著上调,并被发现与增殖和转移有关。然而,其在肝细胞癌(HCC)中的功能作用仍不清楚。我们的研究旨在探讨SLP - 2在HCC细胞增殖、迁移、侵袭、细胞凋亡以及上皮 - 间质转化(EMT)过程中的作用。通过qRT - PCR和免疫组织化学染色评估HCC中SLP - 2 mRNA和蛋白的表达。在体外,我们分别通过CCK - 8、transwell和流式细胞术检测确定细胞增殖、迁移、侵袭和细胞凋亡情况。发现SLP - 2在HCC组织的mRNA和蛋白水平均上调,其异常过表达与HCC患者的不良预后相关。通过siRNA下调SLP - 2可显著抑制体外细胞增殖、迁移、侵袭、抗凋亡能力,并抑制EMT过程。总之,本研究首次证明了SLP - 2在HCC组织中的过表达。作为参与细胞增殖、迁移、侵袭、细胞凋亡和EMT的有效调节因子,SLP - 2可能成为高表达SLP - 2的HCC患者的新型治疗靶点。